Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 5
  1. Immunoglobulin, intravenously. Both immunoglobulin administered intravenously (IVIg) and plasmapheresis have demonstrated benefits in treating patients with GBS. Both treatments improve time to clinical recovery, defined as either discontinuing mechanical ventilation or regaining independent ambulation. IVIg should be given at a dosage of 0.4 g/kg daily for 5 days, and 4 or 5 plasma exchanges of 3.5 to 4 L can be performed on alternate days over a period of 1 to 2 weeks. Complications are more common with plasmapheresis (eg, hypotension, line sepsis) than with IVIg (eg, headaches, myalgias, fevers, chills). Administration of corticosteroids, antibiotics, pyridostigmine, and interferon beta has no proven therapeutic benefit in patients with GBS.

     Pascuzzi RM, Fleck JD. Acute peripheral neuropathy in adults. Guillain-Barré syndrome and related disorders. Neurol Clin 1997;15:529-47.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj